Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)

0
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
ABBV-8E12N/A3 trials
Active Trials
NCT03744546No Longer Available
NCT03413319Completed3Est. Nov 2019
NCT02985879Terminated378Est. Nov 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbVieABBV-8E12
AbbVieABBV-8E12

Clinical Trials (3)

Total enrollment: 381 patients across 3 trials

A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)

Start: Dec 2016Est. completion: Nov 2019378 patients
Phase 2Terminated

Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

Start: Apr 2018Est. completion: Nov 20193 patients
Phase 1Completed

Expanded Access to ABBV-8E12

N/ANo Longer Available

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space